WAIVER AND CONSENT LETTERWaiver and Consent Letter • September 26th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances)
Reference is made to the business combination agreement (the “Agreement”) dated as of May 16, 2023, by and among Forbion European Acquisition Corp. (“FEAC”), enGene, Inc. (the “Company”) and enGene Holdings Inc. (“Newco” and, together with FEAC and the Company, the “Parties”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
